MICROBIOTEC SRL

Their core work

MICROBIOTEC is an Italian biotech SME specializing in vaccine immunology research, with deep expertise in systems vaccinology and immune response profiling. They provide analytical and laboratory services for clinical vaccine trials, particularly focused on characterizing immunogenicity signatures and T-cell responses. Their core contribution to EU consortia is translating complex immune data — transcriptomics, biomarker identification — into actionable insights for vaccine development pipelines.

What they specialise in

How they've shifted over time

MICROBIOTEC entered H2020 through highly focused Ebola vaccine work (2015-2019), contributing to the international VSV-ZEBOV clinical development effort across two consecutive projects. By 2019, they broadened their scope with VacPath, moving from a single-pathogen focus to a more general vaccine technology platform addressing multiple intracellular pathogens. This progression from applied clinical support to broader vaccine vector R&D suggests growing scientific ambition and capability.

Moving from pathogen-specific vaccine analysis toward platform-level vaccine vector technologies and CD8+ T-cell immunology, positioning them for next-generation vaccine development partnerships.

How they like to work

MICROBIOTEC operates exclusively as a consortium participant, never leading projects — typical for a specialist SME that brings specific technical capabilities rather than project management capacity. With 19 unique partners across 10 countries from just 3 projects, they work in large, internationally diverse consortia (consistent with IMI2 and MSCA networks). This profile suggests a reliable technical contributor that integrates well into multi-partner teams without requiring a central coordination role.

Despite only 3 projects, MICROBIOTEC has built a broad network of 19 partners across 10 countries, reflecting the large consortium sizes typical of IMI2 public-private partnerships and MSCA training networks. Their geographic reach spans well beyond Italy into a pan-European and likely global network shaped by the international Ebola vaccine development effort.

What sets them apart

MICROBIOTEC occupies a niche at the intersection of microbiology services and computational vaccinology — rare for a Tuscan SME. Their participation in IMI2 (industry-academia partnerships) alongside standard research actions shows they can bridge the gap between pharmaceutical industry needs and academic research. For consortium builders, they offer hands-on immune profiling and systems biology expertise without the overhead or competing interests of a large pharma partner.

Highlights from their portfolio

• VSV-EBOPLUS
  Largest funding (€485K) and longest duration (2016-2023), representing their most substantial engagement — a systems-level analysis of Ebola vaccine responses in both adults and children under the IMI2 framework.
• VacPath
  Marks a strategic pivot from Ebola-specific work to broader vaccine vector technology via an MSCA training network, signaling investment in next-generation capabilities and workforce development.